Testing IAP0971 for advanced solid tumors and lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic solid tumors that standard treatments didn't help, or you have NSCLC that is stage IIIB/IIIC or IV and has high PD-L1 levels.
- You have at least one tumor that can be measured on scans.
- Your daily activities are not severely limited (ECOG score 0 or 1), and your doctor expects you to live at least 3 more months.
- You have not had certain immunotherapy treatments before, and your last cancer treatment was at least 4 weeks ago.
- Your organs are working well enough, based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IBB0979 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the right dose and see if the drug can shrink tumors.
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.